Male Pattern Baldness in Relation to Prostate Cancer–Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study by Zhou, Cindy Ke et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Epidemiology and Biostatistics Faculty Publications Epidemiology and Biostatistics
2016
Male Pattern Baldness in Relation to Prostate
Cancer–Specific Mortality: A Prospective Analysis
in the NHANES I Epidemiologic Follow-up Study
Cindy Ke Zhou
Paul H Levine
George Washington University
Sean D. Cleary
George Washington University
Heather J. Hoffman
George Washington University
Barry I Graubard
See next page for additional authors
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/sphhs_epibiostats_facpubs
Part of the Biostatistics Commons, and the Epidemiology Commons
This Journal Article is brought to you for free and open access by the Epidemiology and Biostatistics at Health Sciences Research Commons. It has
been accepted for inclusion in Epidemiology and Biostatistics Faculty Publications by an authorized administrator of Health Sciences Research
Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
epub ahead of print
Authors
Cindy Ke Zhou, Paul H Levine, Sean D. Cleary, Heather J. Hoffman, Barry I Graubard, and Michael B. Cook
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/
sphhs_epibiostats_facpubs/255
Original Contribution
Male Pattern Baldness in Relation to Prostate Cancer–Specific Mortality:
A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study
Cindy Ke Zhou, Paul H. Levine, Sean D. Cleary, Heather J. Hoffman, Barry I. Graubard, and
Michael B. Cook*
* Correspondence to Dr. Michael B. Cook, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics,
National Cancer Institute, 9609 Medical Center Drive, Room 7-E106, MSC 9774, Bethesda, MD 20892-9774 (e-mail: michael.cook@nih.gov).
Initially submitted April 14, 2015; accepted for publication July 10, 2015.
We used male pattern baldness as a proxy for long-term androgen exposure and investigated the association of
dermatologist-assessed hair loss with prostate cancer–specific mortality in the first National Health and Nutrition
Examination Survey Epidemiologic Follow-up Study. From the baseline survey (1971–1974), we included 4,316
men who were 25–74 years of age and had no prior cancer diagnosis. We estimated hazard ratios and used
Cox proportional hazards regressions with age as the time metric and baseline hazard stratified by baseline age.
A hybrid framework was used to account for stratification and clustering of the sample design, with adjustment for
the variables used to calculate sample weights. During follow-up (median, 21 years), 3,284 deaths occurred; pros-
tate cancer was the underlying cause of 107. In multivariable models, compared with no balding, any baldness was
associated with a 56% higher risk of fatal prostate cancer (hazard ratio = 1.56; 95% confidence interval: 1.02, 2.37),
and moderate balding specifically was associated with an 83% higher risk (hazard ratio = 1.83; 95% confidence
interval: 1.15, 2.92). Conversely, patterned hair loss was not statistically significantly associated with all-causemor-
tality. Our analysis suggests that patterned hair loss is associated with a higher risk of fatal prostate cancer and
supports the hypothesis of overlapping pathophysiological mechanisms.
cohort; male pattern baldness; prostate cancer mortality
Abbreviations: CI, confidence interval; HR, hazard ratio; NCHS, National Center for Health Statistics; NHANES I, first National
Health and Nutrition Examination Survey; NHEFS, NHANES I Epidemiologic Follow-up Study; PLCO, Prostate, Lung, Colorectal
and Ovarian Cancer Screening Trial.
In US men, prostate cancer is the most frequently diag-
nosed nonskin cancer and the second leading cause of cancer
deaths, with an estimated 238,590 new cases and 29,720
deaths in 2013 (1). Established risk factors for prostate cancer
are limited to older age, black race, family history of prostate
cancer (2), and certain genetic polymorphisms (3), which
collectively explain only a fraction of the disease occurrence.
More studies are needed to better understand the etiology of
prostate cancer, especially lethal malignancies, given that the
current screening tests for prostate cancer lead to substantial
overdiagnosis (4).
Male pattern baldness (also known as androgenic alopecia)
is progressive scalp hair loss due to androgenic miniaturiza-
tion of hair follicles. Generally, 3 zones of the scalp are
preferentially affected: the bitemporal, frontal, and vertex
areas. The prevalence and extent of baldness increase with in-
creasing age (5). Evidence has suggested that male pattern
baldness and prostate cancer might share similar pathophys-
iological mechanisms in terms of heritability and endoge-
nous hormones. For example, heritable factors contribute to
approximately 42% of prostate cancer risk (6) and 81% of
male pattern baldness (7). Regarding endogenous hormones,
androgenic action has been shown to play integral roles in
hair loss and prostate cancer progression; both hair follicles
and the prostate gland are androgen responsive. However, re-
sults from prior epidemiologic studies of circulating sex ste-
roid hormones in relation to prostate cancer risks have been
inconsistent (8–12). All of such prior studies only quantitated
1
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sex steroid hormones at a single time point,mainly atmidlife or
older. Thus, intra-individual variation and/or the etiologically
relevant timewindow of exposure (13, 14)might not have been
adequately captured. Male pattern baldness might be a marker
of long-term androgen exposure and thus could be useful in
aiding our understanding of prostate cancer etiology.
Prior studies of male pattern baldness in relation to prostate
cancer risks have been inconsistent in the methods used and
the conclusions drawn. In most prior studies, investigators
have used a case-control study design, and a meta-analysis
of 7 such studies suggested a 25% higher risk of prostate can-
cer (odds ratio = 1.25; 95% confidence interval (CI): 1.09,
1.44) for men with any vertex balding compared with men
with no balding (15). In prospective studies, researchers
have found somewhat similarly positive associations between
these 2 conditions. An analysis of the Melbourne Collabora-
tive Cohort Study (MCCS) suggested that vertex balding
(Norwood-Hamilton scale types III vertex–VII) at 40 years
of age might predict earlier onset of prostate cancer (16). In
our prior analysis of the Prostate, Lung, Colorectal and Ovar-
ian Cancer Screening Trial (PLCO) cohort, we found that
men with frontal plus moderate vertex balding (Norwood-
Hamilton scale types V–VI) at age 45 years had a 39% higher
risk of aggressive prostate cancer (hazard ratio (HR) = 1.39;
95% CI: 1.07, 1.80) (17). However, we did not observe asso-
ciations between classes of baldness and prostate cancer risks
in the cohort of Vitamins and Lifestyle (VITAL) Study (18),
although vertex balding was captured as a single exposure
class—a categorization that produced a similarly null result
when assessed in our PLCO analysis. Lastly, results from a
former prospective analysis in the first National Health and
Nutrition Examination Survey (NHANES I) Epidemiologic
Follow-up Study (NHEFS), which included follow-up until
1992, suggested a 50% higher risk of incident prostate cancer
for men with any baldness at baseline compared with men
with no balding (19). In that prior analysis of NHEFS data,
investigators could not assess the association of baldness
with fatal prostate cancer because too few deaths from pros-
tate cancer occurred (19). With an additional 20 years of
follow-up, we used the unique resource of the NHEFS,
which has the major advantage of data on dermatologically
assessed baldness at baseline, to investigate the relationship
between male pattern baldness and prostate cancer–specific
mortality.
METHODS
NHANES I is a nationally representative, cross-sectional
survey of the US civilian, noninstitutionalized population
aged 1–74 years in 1971–1974. The complex survey design of
NHANES I is an area-based, multistage, stratified probability
cluster sample of persons with oversampling of elderly peo-
ple, preschool children, personswho live in poverty areas, and
women of child-bearing age (20). Sample weights are func-
tions of the probability of selection with adjustment for non-
response (within family income groups) and poststratification
(calibrated by age-, race-, and sex-specific controls from the
US Bureau of the Census) (21). Five variables (age, residence
in a poverty area, family income group, race, and sex) were
used to calculate sample weights. NHANES I was extended
to 1975 by samplingmore adults 25–74 years of agewhowere
selected to undergo a detailed health examination using a
similar sample design but without oversampling (known as
NHANES I Augmentation) (20). The NHEFS, a longitudinal
prospective study, was conducted among individuals whowere
25–74 years at the NHANES I or NHANES I Augmentation
baselines (21). The NHEFS included a series of follow-up sur-
veys in 1982–1984, 1986, 1987, and 1992 to collect updated
data on time-varying exposures, as well as vital and health sta-
tuses. Complex survey analytic methods are needed to account
for the sampling design and to estimate the appropriate standard
errors. Data collection methods for the NHEFS were approved
by the US National Center for Health Statistics (NCHS) Ethics
Review Board.
Exposure ascertainment
Baldness was classified at baseline dermatologic examina-
tions only for NHANES I participants (1971–1974). The ex-
tent and impression of etiology of baldness were assessed by
trained third-year dermatology residents using a standard pro-
cedure (22). The extent of baldness was categorized into 4
levels (23): 1) none (no obvious baldness at first encounter
or examination); 2) minimum (no obvious baldness at first
encounter but baldness detected during the examination);
3) moderate (observable baldness at first encounter); and
4) severe (obvious baldness at first encounter and hair con-
fined to scalp fringes if present). The impression of etiologies
determined by dermatology residents included patterned hair
loss, alopecia areata, infection, antimetabolites, trauma, and
postclimacteric hair loss. Only individuals deemed to have
patterned hair loss (“male pattern baldness”) were of interest
and were retained for analysis.
Outcome ascertainment
Vital information was ascertained from death certificates
during active follow-up of the NHEFS through 1992; 90%
of participants were successfully traced, and death certificates
were available for 98% of decedents (24). Additional follow-up
has been extended through December 31, 2011, via the linkage
of the NHEFS to the National Death Index since 1979, with
supplemental data sources (e.g., Social Security Administra-
tion, the Centers for Medicare and Medicaid Services, or
death certificate review) to aid determination of vital status.
The linkage used a probabilistic algorithm and manual re-
views at the NCHS (25). The criteria for true matches were
calibrated using samples with active follow-up, 98.5% of
which were correctly classified (26). Prostate cancer as the
underlying cause of death was coded as International Classi-
fication of Diseases, Ninth Revision code 185 from 1971–
1998 (27) and International Classification of Diseases,
Tenth Revision code C61 from 1999 onward. Classification
of prostate cancer as the underlying cause of death remained
consistent across revisions (28). Multiple cause of death data
were also derived from the original coding of death certifi-
cates by the Division of Vital Statistics at NCHS. Each
death certificate contains a single underlying cause of death
and up to 20 additional multiple causes. Outcome informa-
tion was assessed through the NCHS Research Data Center,
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in which analysis of deidentified restricted data was approved
by the NCHS Ethics Review Board.
Study sample
Of the 4,478 men from the NHANES I (1971–1974) part
of the NHEFS, we excluded 49 who had baldness due to rea-
sons other than patterned hair loss, 91 men with a prior cancer
diagnosis, and 22 men without a valid National Death Index
record match or any other source of mortality information.
This resulted in 4,316 men in the NHEFS analytic cohort.
Statistical analysis
Because of the prior statistical studies in which investi-
gators showed overestimation of standard errors caused by
using the highly variable NHEFS sampleweights in weighted
analyses (21), we used a hybrid framework to account for
stratification and clustering of the sampling design while ad-
justing for 4 applicable variables (age modeled as the timemet-
ric, residence in a poverty area (yes vs. no), family income
group (<$3,000; $3,000–$6,999; $7,000–$9,999; $10,000–
$14,999; or ≥$15,000), and race (black vs. nonblack)) that
were used in the calculation of sample weights (29). If data
were missing for family income (4%), the value was imputed
by drawing from a uniform distribution,U(0,1), conditioned on
the observed income distribution. We used 2 additional frame-
works as sensitivity analyses: 1) a model-based framework in
which we ignored the complex survey design and 2) a design-
based framework into which we incorporated stratification,
clustering, and sample weights.
Congruent with the hybrid framework discussed, we used
Rao-Scott F χ2 statistics to account for clustering and stratifi-
cation, with each subject’s sampling weight set at 1 to test the
independence of baseline characteristics relative to degree
of baldness and case status. Therefore, unweighted column
percentages and standard errors were presented as the main
results. We used Cox proportional hazards regressions with
age as the time metric and baseline hazard stratified by age
at interview (50 one-year strata for ages 25–74 years) (30)
to estimate hazard ratios and 95% confidence intervals for
associations between male pattern baldness and prostate
cancer–specific mortality. Follow-up started at the baseline
interview and continued until the time of an event (death from
prostate cancer) or of right-censoring (loss of follow-up, death
from other causes, or last date of follow-up (December 31,
2011)), whichever occurred first. We also examined male
pattern baldness in relation to prostate cancer listed as the un-
derlying cause of death or as 1 of multiple causes of death, as
well as in relation to all-cause mortality, using the hybrid
framework. Additional potential confounders for multivariable
modelswere determined a priori (family historyof prostate can-
cer) or by including covariates individually (educational level,
marital status, region, physical activity level, body mass index
(weight (kg)/height (m)2), cigarette smoking, and alcohol con-
sumption), with retention requiring a 10% change in the hazard
ratios. The proportional hazard assumptionwas tested by visual
inspection of log-log plots and by including interaction terms
of exposure and indicators of time intervals based on tertiles of
the time-to-event distribution.
Interactions of baldness with race and body mass index
(continuous and categorical) were each independently as-
sessed through inclusion of an interaction term in Cox mod-
els. Models were stratified by age group (<65 years vs. ≥65
years) to examine whether age at dermatologic examination
modified the association of baldness with prostate cancer–
specific mortality. Two-sided P values <0.05 were consid-
ered statistically significant. SAS, version 9.3 (SAS Institute,
Inc., Cary, North Carolina) was used for descriptive analyses.
Models were fitted in STATA, version 13 (StataCorp LP,
College Station, Texas).
RESULTS
During follow-up (median, 21 years), 3,284 deaths oc-
curred. Prostate cancer was listed as the underlying cause of
death for 107 men and as 1 of multiple causes of death for 22
men. The median age at interview was 54 years (interquartile
range, 39–67). Table 1 shows unweighted characteristics by
severity of male pattern baldness. The prevalence and extent
of male pattern baldness appeared to increase with increasing
age and lower educational level. Men with moderate to severe
baldness were more likely to have lower family incomes, to
abstain from alcohol, to be black, and to be a former smoker.
Web Table 1 (available at http://aje.oxfordjournals.org/) shows
unweighted characteristics by case status. Consistent with lit-
erature, advancing age, black race, and family history of pros-
tate cancer were associated with prostate cancer–specific
mortality. Differences in prostate cancer–specific mortality
were also observed by educational level, smoking status, and
frequency of alcohol consumption.
As shown in Table 2, after adjustment for applicable vari-
ables used to calculate sampleweights, anybaldnesswas asso-
ciated with a 56% higher risk of prostate cancer–specific
mortality (HR = 1.56; 95% CI: 1.02, 2.37), and moderate
balding specifically was associated with an 83% higher risk
of the outcome (HR = 1.83; 95% CI: 1.15, 2.92), each com-
pared with no balding. The proportional hazard assumption
held for male pattern baldness (P = 0.709). Conversely, male
pattern baldness was unrelated to all-cause mortality. Addi-
tional inclusion of potential confounders did not materially
change the risk estimates. Estimates for the redefined outcome
determined by combining prostate cancer as the underlying
cause and as 1 of multiple causes of death were slightly atten-
uated, although moderate balding was still associated with a
54% higher risk of this composite outcome (HR = 1.54; 95%
CI: 1.00, 2.37) compared with no balding (Web Table 2). Re-
sults obtained in hybrid Coxmodelswere consistent with those
from model-based and designed-based frameworks (Web
Table 3). We found no significant interaction of race (P =
0.624), body mass index at baseline (continuous P = 0.402;
categorical P = 0.290), or age at dermatologic examination
(data not shown) with male pattern baldness.
DISCUSSION
In the present prospective analysis, any baldness was signif-
icantly associated with a 56% higher risk of prostate cancer–
specific mortality compared with no balding. The greatest
specific risk was conferred by moderate balding, which was
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associated with an 83% higher risk. No association was found
between male pattern baldness and all-cause mortality.
To our knowledge, this is the first study in which male pat-
tern baldness has been investigated in relation to prostate
cancer–specific mortality. Results obtained in this analysis
may be supported by those from prior studies of hair loss pat-
terns and aggressive prostate cancer. In a matched case-control
study fromAustralia, Giles et al. (31) found that vertex balding
(Norwood-Hamilton scale types III vertex–V) was associated
with a 2-fold increased risk (odds ratio = 2.04, 95% CI: 1.35,
3.08) of high-grade prostate cancer (Gleason score = 8–10)
compared with no balding. Our analysis of PLCO data sug-
gested that moderate frontal balding (Norwood-Hamilton
scale types V–VI) at 45 years of age was positively associated
with “aggressive” prostate cancer (HRs = 1.39–2.02) (17). In
addition, in a former NHEFS analysis with follow-up through
1992 (and thus with more than two thirds of the accrual time
in the period before widespread use of the prostate-specific
antigen test to diagnose prostate cancer, when symptomatic
prostate cancer predominated), researchers reported a 50%
increased risk of incident prostate cancer (HR = 1.50; 95%
CI: 1.12, 2.00) for men with any baldness and a slightly higher
risk estimate for menwithmoderate baldness (HR = 1.60; 95%
CI: 1.15, 2.23) compared with men with no balding (19).
Similar to these nonlinear relationships observed within our
PLCO analysis and the previous NHEFS analysis, we failed
to identify a dose-response relationship between degrees
of male pattern baldness and prostate cancer–specific mortal-
ity. This could be due to lack of statistical power because
there were only 12 deaths in the group with severe baldness.
Additionally, it could be explained by the perhaps incorrect
assumption that the degree of male pattern baldness is
linearly associated with an underlying exposure (e.g., circulat-
ing androgen concentrations), which in turn shares a linear
Table 1. Unweighted Characteristics of Study Participants by Severity of Male Pattern Baldness, National Health and Nutrition Examination
Survey I Epidemiologic Follow-up Study, 1971–2011
Characteristic
No Balding
Balding Severity
P ValuecMinimum Moderate Severe
No.a % SEb No.a % SEb No.a % SEb No.a % SEb
Age at interview, years <0.0001
25–44 1,073 47.5 1.57 189 25.2 2.07 153 15.3 0.95 31 10.2 2.14
45–54 372 16.5 0.91 156 20.8 1.46 182 18.2 1.05 40 13.2 2.40
55–64 246 10.9 0.78 108 14.4 1.41 163 16.3 1.05 46 15.1 2.08
65–74 570 25.2 1.39 297 39.6 2.29 503 50.2 1.63 187 61.5 3.07
Residence in poverty area 0.369
Yes 1,019 45.1 3.03 328 43.7 4.35 490 49.0 3.04 138 45.4 3.87
No 1,242 54.9 3.03 422 56.3 4.35 511 51.0 3.04 166 54.6 3.87
Resident region 0.993
Northeast 490 21.7 1.44 161 21.5 2.89 227 22.7 2.64 55 18.1 2.65
Midwest 540 23.9 1.68 179 23.9 4.55 238 23.8 2.74 74 24.3 3.69
South 591 26.1 2.43 210 28.0 3.74 250 25.0 2.42 93 30.6 4.50
West 640 28.3 2.03 200 26.7 3.47 286 28.6 2.20 82 27.0 4.88
Family income, $ <0.0001
<3,000 274 12.1 1.27 120 16.0 2.46 164 16.4 1.75 68 22.4 2.80
3,000–6,999 512 22.6 0.93 166 22.1 1.93 244 24.4 1.41 86 28.3 2.24
7,000–9,999 499 22.1 1.14 164 21.9 1.72 213 21.3 1.17 51 16.8 2.00
10,000–14,999 479 21.2 1.05 150 20.0 1.65 164 16.4 1.20 40 13.2 1.73
≥15,000 405 17.9 1.15 123 16.4 1.52 169 16.9 1.60 40 13.2 1.68
Race 0.006
Nonblack 1,855 82.0 1.62 656 87.5 2.05 866 86.5 1.77 255 83.9 2.26
Black 406 18.0 1.62 94 12.5 2.05 135 13.5 1.77 49 16.1 2.26
First-degree relative(s) with prostate cancerd 0.805
No 2,190 96.9 0.45 730 97.3 0.52 966 96.5 0.58 295 97.0 0.88
Yes 71 3.1 0.45 20 2.7 0.52 35 3.5 0.58 9 3.0 0.88
Marital status 0.122
Singlee 404 17.9 0.77 134 17.9 1.54 159 15.9 1.20 66 21.7 2.28
Married 1,857 82.1 0.77 615 82.0 1.57 839 83.8 1.19 238 78.3 2.28
Table continues
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association with aggressive/fatal prostate cancer. An increased
understanding of what drives differential susceptibility of hair
follicle miniaturization by scalp area might provide a better in-
dication of the exposure(s) that underlies both male pattern
baldness and aggressive/fatal prostate cancer. The null associ-
ations between male pattern baldness and all-cause mortality
might be interpreted to indirectly support our hypothesis of
shared exposures between male pattern baldness and prostate
cancer, as it shows that it is not merely a risk factor for overall
mortality. Deaths with prostate cancer as the underlying cause
comprised less than 1% of total deaths among USmen in 2011
(32). Ischemic heart disease has previously been reported to be
positively associated with male pattern baldness (33, 34); the
null result in this study of male pattern baldness and all-cause
mortality does not contradict these findings, given the fact that
this underlying cause of death accounted for a small fraction
(15%) of the total deaths observed.
Despite the inconsistent results from epidemiologic studies
of the associations betweenmale pattern baldness and the risk
of prostate cancer (15, 16, 19, 31, 35–43), clinical observations
and laboratory studies support a link between these 2 condi-
tions. In addition to the fact that both conditions show degrees
of heritability, androgenic action appears to be involved in
the development of male pattern baldness, as well as prostate
carcinogenesis and tumor progression. Men who were born
with a congenital deficiency of type II 5α-reductase, which
normally converts testosterone to dihydrotestosterone, or
who were prepubertally castrated do not develop prostate
cancer and show complete retention of scalp hair (44). Patients
with androgen insensitivity due to deleterious mutations in the
androgen receptor gene present impaired development of the
prostate gland (45) and do not appear bald (46). Balding scalp
is characterized by elevated dihydrotestosterone levels (36, 47,
48). Finasteride, a type II 5α-reductase inhibitor, has been
Table 1. Continued
Characteristic
No Balding
Balding Severity
P ValuecMinimum Moderate Severe
No.a % SEb No.a % SEb No.a % SEb No.a % SEb
Highest education attainment <0.0001
Less than high school 669 29.6 1.37 292 38.9 2.76 444 44.4 2.69 144 47.4 3.03
High school graduate 987 43.7 1.28 301 40.1 2.20 342 34.2 2.00 94 30.9 2.98
Some college/graduate 573 25.3 1.33 153 20.4 1.69 203 20.3 1.93 63 20.7 2.72
Usual and recreational physical activity 0.041
Very inactive 179 7.9 0.66 66 8.8 1.34 91 9.1 0.93 36 11.8 1.61
Inactive 401 17.7 0.95 128 17.1 1.51 219 21.9 1.38 59 19.4 2.03
Moderate 844 37.3 1.03 294 39.2 1.80 360 36.0 1.54 102 33.6 2.13
Active 439 19.4 0.95 132 17.6 1.47 188 18.8 1.31 50 16.4 2.25
Very active 398 17.6 1.18 130 17.3 1.88 143 14.3 1.26 57 18.8 2.36
Body mass indexf 0.545
<25.0 1,035 45.8 1.08 322 42.9 2.22 465 46.5 1.48 127 41.8 3.01
25.0–29.9 934 41.3 0.94 333 44.4 2.07 406 40.6 1.54 133 43.8 2.98
≥30.0 292 12.9 0.61 95 12.7 0.99 130 13.0 1.00 44 14.5 2.03
Smoking status <0.0001
Never 551 24.4 1.02 198 26.4 1.88 254 25.4 1.73 86 28.3 2.33
Former 514 22.7 0.94 192 25.6 1.63 290 29.0 1.62 84 27.6 2.38
Current 889 39.3 1.43 265 35.3 1.86 299 29.9 1.60 84 27.6 2.77
Average number of drinks per week 0.001
None 593 26.2 1.08 212 28.3 1.86 328 32.8 2.48 103 33.9 2.87
≤2 496 21.9 0.73 129 17.2 1.27 214 21.4 1.47 62 20.4 1.97
3–7 419 18.5 1.11 158 21.1 1.65 155 15.5 1.36 46 15.1 1.85
8–14 279 12.3 0.78 87 11.6 1.24 103 10.3 1.16 26 8.6 2.01
≥15 276 12.2 0.74 70 9.3 0.97 101 10.1 1.00 28 9.2 2.26
Abbreviation: SE, standard error.
a Column percentages may not add up to 100% because of missing values.
b Unweighted standard errors were calculated by accounting for clustering and stratification in a hybrid statistical framework.
c P value was calculated from Rao-Scott F χ2 tests using nonmissing categories to account for clustering and stratification.
d In the 1982–1984 or 1992 follow-up survey.
e Includes widowed, divorced, separated, and never married.
f Weight (kg)/height (m)2.
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approved by the US Food andDrugAdministration to stop hair
loss and stimulate hair growth. Similarly, castration has long
been shown to shrink the primary cancerous lesion in patients
with advanced prostate cancer, whereas injection of androgens
aggravates the condition (49). However, associations between
concentrations of circulating sex steroid hormones and prostate
cancer risk are inconsistent (8–12), possibly because of a com-
bination of variability in the robustness and detection limits of
steroid quantitation methods used; assessment of a limited
number of metabolites within the sex steroid hormone biosyn-
thesis pathway; and variable case mixes recruited before and/
or during the period in which there was widespread use of
the prostate-specific antigen test to diagnose prostate cancer.
In a pooled analysis of 18 prospective studies in which in-
vestigators used study-specific categorization of circulating
hormone concentrations, free testosterone concentration
was positively associated with incident prostate cancer risk
in the period before widespread use of the prostate-specific
antigen test to diagnose prostate cancer (9). Moreover, in a
recent nested case-control study in the PLCO cohort, Weiss
et al. (8) reported that the ratio of serum testosterone to sex
hormone-binding globulin was positively associated with
aggressive prostate cancer in men older than 65 years of
age. However, prediagnostic circulating sex hormone levels
were unrelated to lethal prostate cancer (metastasized cancer
or death) in a case-control study nested in the Physicians’
Health Study (PHS) and the Health Professionals Follow-up
Study (HPFS) (10). Nevertheless, prior studies were limited
by a single measurement of sex steroid hormones in midlife
or later. Fluctuations of sex steroid hormones in early life or
cumulative androgen exposure may be more etiologically
relevant (50).
There are limitations to our NHEFS analysis. Distinct pat-
terns of baldness were not fully captured by degrees of hair
loss. The relationship of these 2 conditions may depend on
the scalp areas in which the balding occurs, as we have dis-
cussed, and thus a combination of frontal and vertex baldness
in NHEFS might have attenuated our risk estimates for fatal
prostate cancer. The limited number of men younger than
45 years of age at baseline (n = 1,446; 8 cases) precluded
assessment of early-onset baldness in relation to fatal prostate
cancer with statistical power. Previous case-control studies
have suggested that early-onset baldness may be more strongly
associated with incident prostate cancer (38, 42, 43). The lim-
ited number of black men in our analytic cohort (n = 684; 32
cases) may be the reason why the similar relative risks for fatal
prostate cancer in men with any baldness using the full cohort
were not statistically significant in this racial group alone (HR =
1.76; 95% CI: 0.75, 4.11). In a previous analysis of NHEFS
data, investigators reported that black men with any baldness
had a more than 2-fold higher risk of incident prostate cancer
(HR = 2.10; 95% CI: 1.04, 4.25), with a slightly lower risk for
nonblack men (HR = 1.42; 95% CI: 1.01, 1.98) (19). Results
fromacase-control study inblackmen (318 cases, 219 controls)
further suggested that frontal baldness at 30 years of age was
associated with high-stage (odds ratio = 2.61; 95% CI: 1.10,
6.18) and high-grade (odds ratio = 2.20; 95% CI: 1.05, 4.61)
prostate cancer (51). Misclassification of the underlying
cause of death may slightly attenuate the true association,
given that death certificates were missing for 5% of participants
who died (whowere thus right-censored when death occurred)
and that the estimated agreement for attribution of prostate can-
cer as the underlying cause of death between medical records
review and linkage to death certificates ranged from 87%–97%
(52, 53). Information on prostate cancer screening and treat-
ment was incomplete because of the termination of active
follow-up in 1992. However, wewould expect any effect mod-
ification by screening/treatment to be small, given that themost
current observational trial data indicate a minimal effect of
prostate cancer screening on the reduction of prostate-specific
mortality in USmen (54) and that we adjusted for covariates of
socioeconomic status and accounted for cohort/period effect
by stratifying the baseline hazard. Moreover, even if effect
modification by screening/treatment exists, we would expect
this effect to attenuate the associations observed, assuming
that the distribution of screening and/or treatment are mostly
likely to be nondifferentially distributed by degree of hair
loss. Finally, inferences about the target US population cannot
be drawn, given that the unweighted analysis was performed
for the appropriate estimation of variances.
Table 2. Associations of Male Pattern Baldness With Prostate Cancer–Specific Mortality and All-Cause Mortality,
National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study, 1971–2011
Male Pattern
Baldness
Severity
No. of
Participants
No. of
Person-Years
Prostate Cancer–Specific
Mortality
All-Cause
Mortality
No. of
Deaths HR
a 95% CI No. ofDeaths HR
a 95% CI
None 2,261 57,636 38 1.00 Referent 1,500 1.00 Referent
Any 2,055 38,941 69 1.56 1.02, 2.37 1,784 1.04 0.97, 1.12
Minimum 750 15,500 18 1.17 0.62, 2.22 628 1.05 0.96, 1.16
Moderate 1,001 18,565 39 1.83 1.15, 2.92 880 1.03 0.93, 1.15
Severe 304 4,876 12 1.65 0.82, 3.35 276 1.05 0.92, 1.20
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Age was modeled as the time metric, with baseline hazard stratified by age at interview. Hazard ratios were
estimated by accounting for clustering and stratification in a hybrid statistical framework, with adjustment for
variables that were used to calculate the sample weights, including residence in a poverty area (yes or no), family
income (<$3,000, $3,000–$6,999, $7,000–$9,999, $10,000–$14,999, or ≥$15,000), and race (black or nonblack).
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In summary, we found that compared with no balding, any
baldness was significantly associated with a higher risk of fatal
prostate cancer and that moderate balding specifically was as-
sociated with the highest risk. Our results support the hypoth-
esis of overlapping pathophysiological mechanisms in the 2
conditions. The moderate association and relatively high prev-
alence of male pattern baldness in Western populations does
not currently support the use of male pattern baldness in pros-
tate cancer screening decisions. In future studies, investigators
should aim to confirm the association between male pattern
baldness and fatal prostate cancer, as well as evaluate the ad-
ditional value it may offer to predictive models.
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